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Abstract
Background: Malignant bowel obstruction (MBO) is often a terminal event in end-stage cancer patients. The
decision to intervene surgically is complex, given the risk of harm in patients with a limited lifespan. Therefore, we
sought to compare clinically meaningful outcomes in MBO patients treated with surgical versus medical management
using population-based data.
Methods: We performed a retrospective analysis of hospitalized patients with MBO from 2006 to 2010 using the
California Office of Statewide Health Planning and Development dataset. Hospital-free days (HFDs) at 30-, 90-, and 180-
days were calculated accounting for all hospitalization, emergency department visit, and skilled nursing facility lengths
of stay. Adjusted regression models were used to compare HFDs, disposition, complications, in-hospital death, and
survival for surgical versus medical MBO cohorts, using inverse probability of treatment weighting with propensity
scores.
Results: Of 4576 MBO patients, 3421 (74.8%) were treated medically and 1155 (25.2%) were treated surgically. Surgical
patients had higher rates of complications (44.0% vs. 21.3%, p < 0.0001) and in-hospital death (9.5% vs. 3.9%, p < 0.0001)
with lower rates of disposition to home (76.3% vs. 89.8%, p < 0.0001). Surgical patients had fewer 30- and 90-day HFDs
compared to medical patients (p < 0.01). However, at 180-days, there were no differences in HFDs between treatment
groups. There was no difference in overall survival between surgical and medical patients (median 6.5 vs. 6.4 months).
Conclusion: In this population-based analysis, medical management was associated with less hospital utilization at
30- and 90-days, fewer in-hospital deaths, and more frequent discharges to home. These data underscore the potential
benefits of medical management for MBO patients at the end-of-life.
Keywords: Malignant bowel obstruction, Bowel obstruction, Surgery, Disposition, Hospital utilization, Palliative surgery
Background
Malignant bowel obstruction (MBO) is common among
patients with disseminated malignancy with rates as high
as 28% for gastrointestinal and 51% for gynecologic can-
cers [1]. Moreover, MBO is often a pre-terminal event
with median survival ranging from 1 to 9months after
diagnosis [1–6]. Therefore, a key objective of MBO
management is to achieve optimal palliation with a focus
on relieving debilitating symptoms and optimizing patient
quality of life. Previous studies have shown that there is
significant variation in the approach to MBO, and the de-
cision to treat with either medical or surgical management
is complex [1, 4, 6]. Surgical intervention in advanced can-
cer patients is associated with high risks of morbidity with
potential to adversely impact patient quality of life [7–10].
Prior studies have shown serious complication rates as
high as 44% and readmission rates as high as 74% among
MBO patients treated with palliative surgery [6]. Despite
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these findings, it continues to remain unclear the optimal
palliative treatment for MBO since surgery can offer the
potential for durable symptom palliation, including ob-
struction resolution and resumption of diet [1, 6, 11, 12].
Although treatment guidelines have been formulated
by multidisciplinary physician groups for MBO, the deci-
sion to proceed with medical versus surgical manage-
ment is variable, as it is often determined based the
surgeon’s own clinical experience and/or the patient’s
preferences and goals-of-care [13–15]. The National
Comprehensive Cancer Network guidelines recommend
that the management of MBO be largely guided by pa-
tients’ life-expectancy [13]. Surgical and/or procedural
management should be considered in patients with several
months to years of life remaining, while medical manage-
ment is recommended for those with only months to
weeks of life remaining and for poor surgical candidates
based on known risk factors including ascites, extensive
peritoneal carcinomatosis, multiple sites of obstruction,
and poor functional status. Despite such expert consensus
guidelines, MBO treatment remains variable as such
guidelines have not been well disseminated, thereby allow-
ing physicians’, surgeons’ and patients’ preferences to dir-
ect treatment decisions for MBO.
To date, there have been few population-based analyses
comparing outcomes of surgical and medical treatment of
MBO [1, 6]. The majority of studies have consisted of
retrospective, single institution analyses using patient co-
horts as small as 22 individuals [1, 16]. Notable exceptions
have analyzed outcomes among ovarian, pancreatic, and
colorectal cancer patients in the Medicare population,
thereby limiting the generalizability of the findings to the
elderly population with only those specific cancer diagno-
ses [3–5]. Since MBO frequently occurs among patients
younger than 65 years of age and in the setting of other
malignancies such as gastric and non-ovarian genitouri-
nary cancers, we sought to perform a population-based
analysis encompassing a more heterogeneous patient co-
hort [6, 17]. Furthermore, the vast majority of prior MBO
studies principally focused on survival as the outcome of
interest and have failed to evaluate other important out-
comes related to quality of life and resource utilization. As
such, we sought to analyze additional key metrics, includ-
ing place of death and hospital utilization, which are
largely absent in current MBO research and palliative sur-
gery research overall [3, 5, 18].
Therefore, the purpose of this study was to address
these current gaps in literature by performing a
population-based analysis comparing clinically meaning-
ful end-of-life outcomes for MBO patients treated with
medical versus surgical management. We specifically
sought to compare in-hospital deaths, disposition to
home, and hospital-free days (HFDs). HFDs is composite
endpoint which incorporates the length of stay (LOS) of
the index hospitalization, readmissions, and skilled nurs-
ing facility visits and survival. We specifically chose this
measure as it is a patient-centered quality metric that re-
flects both resource utilization and end-stage cancer pa-
tients’ goals of avoiding prolonged and repeated
hospitalizations near the end of life [19–21].
Methods
We performed a retrospective analysis of hospitalized pa-
tients with MBO from 2006 to 2010 at all California li-
censed hospitals using the Office of Statewide Health
Planning and Development (OSHPD) death linked data-
set. The OSHPD dataset consists of patient discharge
(PDD), emergency department (EDD), and linked-death
files from the California Department of Public Health vital
statistic records. PDD consists of all patient records for
acute hospitalizations and skilled nursing facility (SNF)
visits from California licensed hospitals and SNFs. EDD
consists of all emergency department visits patient records
from California licensed hospitals. OSHPD has been pre-
viously used as the primary data source for various studies
Fig. 1 Selection of patients with malignant bowel obstruction
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investigating healthcare utilization and patient outcomes
in general surgery and surgical oncology [22–25]. The re-
search protocol was approved by the University of Califor-
nia, Davis Institutional Review Board and the California
Health and Human Services Agency Committee for the
Protection of Human Subjects.
We identified 4803 patients admitted to an acute care
hospital with the diagnosis of MBO from 2006 to 2010
(Fig. 1). MBO was defined using the principal diagnosis of
bowel obstruction and a secondary diagnosis of intra-ab-
dominal metastatic cancer (indicative of stage IV cancer)
based on International Classification of Diseases 9th edi-
tion (ICD-9) codes from OSHPD (see Additional file 1:
Table S1) [4, 26]. We did not include patients with a sec-
ondary diagnosis of bowel obstruction to prevent inclu-
sion of patients who underwent an unrelated surgery and
then experienced a post-operative bowel obstruction. To
ensure complete record of length of hospitalization, we
excluded 213 patients who were transferred from or to an
outside hospital. Fourteen patients who had an operation
performed not standard for MBO such as cholecystec-
tomy, lung resection, and intra-abdominal biopsy were
also excluded to ensure patients were appropriately
assigned to medical and surgical groups. The final cohort
consisted of 4576 patients with MBO. Surgical patients
were defined as patients who underwent one or more of
the following operations from ICD-9 procedure codes (see
supplement) during the first MBO hospitalization: ex-
ploratory laparotomy, adhesiolysis, small or large bowel
resection, enterostomy, colostomy, gastrointestinal or en-
teric bypass, and open gastrostomy. Due to the small
number of procedural interventions alone (94 percutan-
eous gastrostomy tubes and 10 enteric stents), we chose
to include these patients in the medical management co-
hort, as these procedural interventions do not require
general anesthesia and are not associated with the same
recovery time as surgical management for MBO.
Patient covariates assessed included demographics
(age, gender, race, ethnicity), primary cancer diagnosis, med-
ical comorbidities including diagnosis of ascites, and do not
resuscitate (DNR) status. The Elixhauser comorbidity index,
a well-established and previously validated measure of re-
admission and mortality risk based on 29 medical comor-
bidities, was used to assess patient comorbidities [27–30].
Table 1 Patient demographics and clinical characteristics
Medical Management N = 3421 Surgical Management N = 1155 P value
N or Mean % or SD N or Mean % or SD
Age 63.2 13.6 64.6 13.7 0.002
Male 1186 34.7% 414 35.8% 0.47
Race
Caucasian 2132 62.3% 777 67.3% 0.007
Black 230 6.7% 79 6.8%
Asian/Pacific Islander 394 11.5% 129 11.2%
Hispanic 587 17.1% 149 12.9%
Other/Unknown 78 2.3% 21 1.8%
Elixhauser Comorbidity Index Score 19.3 7.9 21.9 9.1 < 0.0001
Ascites 445 13.0% 164 14.2% 0.30
DNR Status 443 13.0% 128 11.1% 0.10
Primary Cancer Diagnosis
Colorectal 1046 30.6% 345 29.9% 0.65
Pancreatic 164 4.8% 57 4.9% 0.85
Ovarian 840 24.6% 220 19.1% 0.0001
Foregut and Small Bowel 213 6.2% 72 6.2% 0.99
Hepatobiliary 78 2.3% 19 1.7% 0.20
Lung/Mediastinal 90 2.6% 38 3.3% 0.24
Nonovarian Urogyn 395 11.6% 134 11.6% 0.96
Other 879 25.7% 218 18.9% < 0.0001
Unknown 509 14.9% 228 19.7% 0.0001
Multiple Cancer Diagnoses 791 23.1% 180 15.6% < 0.0001
SD standard deviation, Urogyn urogynecological
Bateni et al. BMC Cancer         (2018) 18:1166 Page 3 of 10
The primary outcomes were disposition to home,
in-hospital deaths and HFDs. HFDs at 30-, 90-, and
180-days were calculated as the summation of the LOS
for the index MBO hospitalization, readmissions, emer-
gency department visits, and skilled nursing facility stays
subtracted from 30, 90, 180 or days from diagnosis to
death if earlier than the corresponding interval [21, 31].
For example, a patients who is initially hospitalized for
3 days and discharged home only to die 5 days later
would have HFDs of 5 at 30-, 90- and 180-days. A pa-
tient who is initially hospitalized for 14 days, discharged
home for 2 days, readmitted and hospitalized for 20 days,
and subsequently discharged home without any further
readmissions, dying 1 year later, would have HFDs of 2
at 30-days, 56 at 90-days, 148 at 180-days.
Secondary endpoints were complications within
30-days of hospitalization, readmissions within 7- and
30-days of discharge, re-obstruction within 1 year from
first diagnosis (based on ICD-9 codes for emergency de-
partment visits and readmissions), time from discharge
to readmission and re-obstruction, and overall survival.
Thirty-day complications were identified from ICD-9
codes and included pulmonary failure, pneumonia, car-
diac complications, acute renal failure, pulmonary em-
bolus, deep vein thrombosis, hemorrhage, shock, and
wound complications [32–34]. Survival was measured
from the first admission date for MBO to date of death
or last date of vital status follow-up.
Statistical analysis
Patient covariates were presented as means with standard
deviations and frequencies with percentages for continu-
ous and categorical variables unless otherwise stated. Chi
square and student t-tests assessed differences in baseline
covariates and outcomes between groups. Propensity
scores estimating the probability of selection into medical
or surgical management based on patient demographics
(age, race, gender), cancer diagnoses, presence of ascites,
Elixhuaser comorbidity index score, and DNR status were
created. Inverse probability of treatment weighting
(IPTW) based on these propensity scores was used in the
analysis of our primary and secondary endpoints to ad-
dress selection bias for MBO treatment [35, 36]. Covari-
ates balance was determined to be appropriate between
groups with IPTW using standardized differences.
Multinomial logistic regression with IPTW was per-
formed to compare risk of returning home versus
in-hospital death or discharge to facility for surgical and
medical groups. HFDs were observed to have a bimodal
distribution and, consequently, appropriate for a logistic
regression model. We therefore categorized HFDs as less
than or equal to/greater than the median, which was 20
days for 30-day HFDs, 70 days for 90-day HFDs, and 133
days for 180-day HFDs. IPTW logistic regression was per-
formed to evaluate differences in HFDs between groups
and identify predictors of fewer HFDs. Sensitivity analysis
was performed to determine if there were differences in
HFDs between groups when including only hospitaliza-
tions versus including all hospitalizations and SNF visits.
As there were no statistically significant differences ob-
served, we chose to present results for HFDs including
SNF visits.
Logistic regression with IPTW was performed to compare
30-day complications, readmissions, and re-obstruction for
medical and surgical patients. Time-to-event analysis for
readmissions and re-obstruction was performed using the
Fine and Gray competing risk model, accounting for death
as a competing event, with IPTW. Linear regression with
IPTW was performed to compare hospital LOS for the
index admission. Log transformation of LOS was per-
formed to achieve normality in the linear regression
model. Log-rank test with and without IPTW was used to
compare overall survival between treatment groups.
Results
Of the 4576 patients hospitalized with MBO, 3421
(74.8%) were treated with medical management and 1155
(25.2%) were treated with surgery with significant differ-
ences in age, race, comorbidities, and cancer diagnoses be-
tween groups (Table 1). Those treated with surgery were
slightly older (64.6 vs. 63.2 years old, p = 0.002), more
frequently Caucasian (67.3% vs 62.3%, p = 0.007), with
greater Elixhauser comorbidity scores (21.9 vs. 19.3,
p < 0.0001), and were less frequently diagnosed with ovar-
ian cancer (19.1% vs. 24.6%, p = 0.0001) and multiple can-
cer diagnoses (15.6% vs. 23.1%, p < 0.0001). There were
Fig. 2 Disposition for medically managed versus surgically managed
patients with malignant bowel obstruction. Surgical patients had
greater rates of in-hospital death and lower rates of discharge to home
compared to medical patients (p < 0.0001)
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differences in rates of surgical management by year with
27.5% of patients undergoing surgery in 2006, 29.4% in
2007, 23.0% in 2008, 25.7% in 2009, and 21.4% in
2010 (p = 0.0005).
As shown in Fig. 2, surgical patients had greater rates
of in-hospital death (9.5% vs. 3.9%, p < 0.0001) and lower
rates of discharge to home (76.3% vs. 89.8%, p < 0.0001)
in our unweighted analysis. In the IPTW model, surgical
patients had greater odds of in-hospital death (OR 2.28,
95%CI 1.73–3.00, p < 0.0001) and disposition to a facility
(OR 2.34, 95%CI 1.86–2.94, p < 0.0001) compared to
medical patients (Table 2). Additional predictors of both
in-hospital death and disposition to facilities included Elix-
hauser comorbidity scores and DNR status (p < 0.0001 all).
Rates of 30-, 90- and 180-day HFDs greater than each
respective median in the unweighted analyses are shown
in Fig. 3. Surgical patients had greater odds of fewer
HFDs (HFDs below the respective median) at 30-days
Table 2 Univariate (Model 1) and multivariate (Model 2) inverse probability to treatment weighted regression models for patient
disposition from the index hospitalization for malignant bowel obstruction
In-Hospital Deatha Disposition to a Facility a
OR 95% CI P value OR 95% CI P value
Model 1
Treatment
Medical (ref)
Surgery 2.28 1.73 3.00 < 0.0001 2.34 1.86 2.94 < 0.0001
Model 2
Treatment
Medical (ref)
Surgery 2.68 1.99 3.62 < 0.0001 2.65 2.09 3.36 < 0.0001
Age 1.03 1.02 1.05 < 0.0001 1.06 1.04 1.07 < 0.0001
Gender
Female (ref)
Male 1.61 1.13 2.28 0.01 0.99 0.73 1.34 0.95
Race/Ethnicity
Caucasian (ref)
Asian/Pacific Islander 1.07 0.63 1.82 0.80 1.17 0.75 1.82 0.49
Black 1.12 0.59 2.13 0.74 1.89 1.18 3.02 0.01
Hispanic 1.33 0.82 2.16 0.24 1.15 0.74 1.79 0.53
Other/Unknown 0.87 0.30 2.49 0.79 0.69 0.23 2.07 0.51
Elixhauser Comorbidity 1.07 1.05 1.09 < 0.0001 1.04 1.02 1.05 < 0.0001
DNR Order 4.57 3.12 6.70 < 0.0001 2.66 1.86 3.81 < 0.0001
Ascites 1.54 1.02 2.33 0.04 1.13 0.79 1.63 0.50
Cancer Diagnosis
Colorectal (ref)
Ovarian 0.43 0.20 0.90 0.02 0.79 0.48 1.29 0.34
Pancreatic 0.81 0.36 1.84 0.62 0.54 0.23 1.25 0.15
Hepatobiliary 0.13 0.01 1.22 0.07 0.61 0.13 2.78 0.52
Foregut & small bowel 2.09 1.08 4.04 0.03 1.33 0.64 2.76 0.44
Nonovarian Urogyn 1.02 0.56 1.86 0.95 0.76 0.43 1.34 0.34
Lung/Mediastinal 2.60 1.14 5.92 0.02 0.69 0.27 1.76 0.44
Other 0.97 0.44 2.13 0.95 1.53 0.95 2.45 0.08
Unknown 1.02 0.62 1.70 0.95 0.80 0.54 1.19 0.26
Multiple Diagnoses 0.82 0.48 1.38 0.45 0.96 0.63 1.47 0.85
CI confidence interval, Ref reference, Urogyn Urogynecological, aReference is disposition to home in multinomial logistic regression model
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(OR 3.98, 95%CI 3.40–4.67, p < 0.0001) and 90-days
(OR 1.24, 95%CI 1.08–1.42, p = 0.004) compared to medical
patients in the IPTW models (Table 3). However, there
was no difference in HFDs at 180-days in the IPTW model
(OR 0.89, 95%CI 0.77–1.02, p = 0.09). Elixhauser comorbid-
ity scores, DNR status, and ascites were also predictors of
fewer HFDs at 30-, 90-, and 180-days (p < 0.0001 all).
Table 4 presents the unadjusted and IPTW analyses of
our secondary outcomes. Thirty-day complication rates
were greater for surgical patients compared to medical
patients (44.0% vs. 21.3% unweighted, p < 0.0001).
Additionally, surgical patients had longer lengths of stay
for the index admission compared to medical patients
(13 vs. 5 days unweighted, p < 0.0001). However, 7-day
and 30-day readmissions were greater among medical
patients compared to surgical patients (15.2% vs. 10.9%
unweighted, p = 0.0003, and 34.5% vs. 23.4% unweighted,
p < 0.0001 respectively). Re-obstruction was more
frequent among medically managed patients compared to
surgical patients (27.3% vs. 10.5% unweighted, p < 0.0001).
Of those who underwent medical management, 9.5%
underwent an operation for re-obstruction within 1 year
of the initial obstruction, whereas, only 2.2% of surgically
managed patients underwent re-operation during a subse-
quent readmission for re-obstruction. Furthermore, time
to first readmission and re-obstruction was shorter for
medical patients (IPTW sub-hazard ratio (SHR) 0.72,
95%CI 0.66–0.79, p < 0.0001 and IPTW SHR 0.33, 95%CI
0.28–0.43, p < 0.0001, respectively). Tests of statistical sig-
nificance for these analyses were similar with and without
IPTW. Figure 4a/b illustrates the unweighted and IPTW
overall survival stratified by medical versus surgical man-
agement. Overall, there were no differences in survival be-
tween groups with and without IPTW (p > 0.05). Median
survival was 6.4 months for medically managed patients
and 6.5 months for surgically managed patients.
Discussion
In this population-based analysis of end-stage cancer pa-
tients with malignant bowel obstruction, medical manage-
ment was associated with fewer in-hospital deaths and
less hospital utilization, as defined by HFDs, at 30- and
90-days compared to surgical management. However, at
180-days, medical management and surgical management
outcomes were comparable with respect to HFDs. Such
findings were surprising, as they demonstrated that des-
pite the increased rate of readmissions and re-obstruction
associated with medical management described in this
analysis and prior studies [4, 17], cumulative time hospi-
talized was less early on and persisted for at least 90 days
for medical patients compared to surgical patients. These
findings illustrate the complexity associated with palliative
decision-making among MBO patients and the potential
for surgery to negatively impact important quality-of-life
related endpoints in these patients.
As the median survival after diagnosis of MBO was
approximately 6 months in both cohorts, our data
underscore the limited span for these patients and
reinforce the concept that treatment recommendations
must prioritize patient-centered care goals such as pro-
longed and repeated hospitalizations and avoidance of
therapeutic morbidity. Prior research has shown that
end-of-life care at home is preferred by patients and
caregivers [20, 37, 38]. For example, in a survey of Medi-
care beneficiaries, Barnato et al. reported that 86% of
Medicare patients expressed a preference for spending
their time at home at the end-of-life [37]. Similarly,
in-hospital and ICU deaths among end-stage cancer pa-
tients have been associated with worse patient quality of
life and greater caregiver emotional distress [38]. There-
fore, the greater risk of in-hospital death and fewer
HFDs at 30- and 90-days observed in our study among
surgical patients appears to be clinically significant and
may help guide evolving multidisciplinary palliative care
recommendations for patients diagnosed with MBO.
Additionally, our finding of a median survival of 6
months among MBO patients further highlights that the
diagnosis of MBO is a pre-terminal event for most
patients requiring advanced care planning and thought-
ful goals of care discussions at the time of diagnosis, if
not earlier.
This population-based analysis of MBO patients ad-
dresses an important gap in previous research. In con-
trast with prior studies, our patient cohort consisted of
both elderly and non-elderly patients with a variety of
Fig. 3 30-day, 90-day, and 180-day hospital-free days (HFDs) greater
than each respective median for medically managed versus surgically
managed patients with malignant bowel obstruction. Surgical patients
had fewer HFDs at 30 and 90 days compared to medical patients
(p < 0.01). There was no difference between groups in HFDs at
180 days (p > 0.05)
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primary cancer diagnoses receiving care at more than 500
hospitals (although admittedly limited California), thereby,
contributing to the generalizability of our findings. Add-
itionally, we attempted to account for selection bias by
using propensity score IPTW based on measured patient
demographic and clinical characteristics, creating a similar
distribution of each covariate for medical and surgical pa-
tients [36, 39]. We do acknowledge the potential implica-
tions of unmeasured confounders, including severity of
obstruction and patient and physician preferences, and as
such, considered instrumental variable analyses as an al-
ternative approach. Unfortunately, due to absence of an
‘instrumental variable’ (i.e. variable associated with the
treatment, but not directly associated with the primary
outcome), such an approach was not possible. Regardless,
our adjustment of known confounders is a well-validated
methodology to control for potential selection bias within
the limitations of a retrospective dataset.
Table 3 Univariate (Model 1) and multivariate (Model 2) inverse probability to treatment weighted regression models for afewer
hospital-free days at 30, 90 and 180 days
30-Day Hospital-Free Days 90-Day Hospital Free Days 180-Day Hospital Free Days
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Model 1
Treatment
Medical (ref)
Surgery 3.98 3.40 4.67 < 0.0001 1.24 1.08 1.42 0.004 0.89 0.77 1.02 0.09
Model 2
Treatment
Medical (ref)
Surgery 4.54 3.86 5.34 < 0.0001 1.26 1.09 1.46 0.002 0.87 0.75 1.01 0.06
Age 1.00 0.99 1.01 0.97 1.00 1.00 1.01 0.65 1.01 1.00 1.01 0.08
Gender
Female (ref)
Male 1.07 0.90 1.28 0.45 1.09 0.93 1.29 0.30 1.14 0.97 1.34 0.13
Race/Ethnicity
Caucasian (ref)
Asian/Pacific Islander 0.94 0.73 1.21 0.64 1.01 0.80 1.27 0.94 1.05 0.83 1.32 0.69
Black 1.90 1.44 2.49 < 0.0001 1.37 1.03 1.84 0.03 1.22 0.91 1.62 0.18
Hispanic 0.92 0.73 1.17 0.51 1.07 0.86 1.34 0.53 1.13 0.91 1.40 0.28
Other/Unknown 1.13 0.67 1.91 0.66 0.90 0.56 1.43 0.65 0.70 0.45 1.09 0.11
Elixhauser Comorbidity 1.06 1.05 1.07 < 0.0001 1.04 1.03 1.05 < 0.0001 1.04 1.03 1.05 < 0.0001
DNR Status 1.95 1.50 2.54 < 0.0001 2.37 1.82 3.07 < 0.0001 2.60 1.99 3.38 < 0.0001
Ascites 2.04 1.62 2.56 < 0.0001 2.38 1.91 2.97 < 0.0001 2.19 1.75 2.75 < 0.0001
Cancer Diagnosis
Colorectal (ref)
Ovarian 0.79 0.61 1.04 0.09 0.71 0.55 0.92 0.01 0.76 0.59 0.99 0.04
Pancreatic 1.37 0.89 2.12 0.16 1.65 1.09 2.50 0.02 2.24 1.48 3.39 0.0001
Hepatobiliary 1.02 0.42 2.46 0.97 1.86 0.79 4.40 0.16 1.66 0.80 3.44 0.17
Foregut & Small Bowel 1.03 0.65 1.62 0.91 1.46 0.96 2.22 0.07 2.23 1.48 3.35 0.0001
Nonovarian Urogyn 1.37 1.00 1.87 0.05 1.63 1.21 2.19 0.001 1.90 1.11 3.25 0.02
Lung/Mediastinal 0.93 0.51 1.70 0.81 1.27 0.74 2.17 0.38 2.11 1.56 2.88 < 0.0001
Other 0.97 0.69 1.36 0.84 0.75 0.55 1.03 0.07 1.06 0.77 1.45 0.73
Unknown 0.82 0.65 1.04 0.10 0.84 0.67 1.05 0.12 0.91 0.73 1.14 0.41
Multiple Diagnoses 0.99 0.77 1.27 0.95 1.22 0.96 1.54 0.10 1.29 1.02 1.63 0.04
CI confidence interval, Ref reference, Urogyn urogynecological, afewer HFDs defined as below the median HFD for each respective time interval (< 20 days for 30-day
HFDs, < 70 days for 90-day HFDs, and < 133 for 180-day HFDs)
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Our novel study design, including large sample size,
likely contributes to the key findings we observed in our
analysis, particularly with respect to prior studies. For ex-
ample, although in-hospital death and disposition to home
were shown to be equivalent for medical and surgical
management of MBO in a single institution retrospective
study by Henry et al., we observed a significantly greater
risk of in-hospital death and disposition to a facility after
surgical management of MBO [17]. Additionally, although
small single-institution retrospective studies of MBO have
observed greater survival for surgical patients with re-
ported increases in median survival ranging from 2 to 5
months, we and population-based studies consisting of
elderly cohorts have shown equivalent survival between
medical and surgical patients [3–5, 17, 40, 41]. Such differ-
ences reflect the value of using population-based data to
investigate these challenging clinical problems.
Despite the strengths of our study and the clinically
meaningful findings, it is nevertheless important to ac-
knowledge potential limitations and implications for fu-
ture research. Although we used IPTW to adjust for
key measured confounding factors, we were not able to
obtain data on and adjust for important clinical patient
and disease characteristics including cancer burden,
performance status, severity or location of bowel ob-
struction, as well as surgeon and patient preferences
and hospital-level variation. This is a current limitation
of administrative databases, including OSHPD. More-
over, we were not able to evaluate differences in symp-
tomatic relief (i.e. restoration of diet and pain) or
directly assess quality of life following medical versus
surgical treatment. The few studies comparing symp-
tom relief with medical versus surgical management of
MBO presently consist of single-institution cohorts [17,
41]. Although each of these studies found equivalent
rates of symptom resolution, more research is needed
to better understand these questions. Furthermore, we
did not separately evaluate patients who underwent
procedural interventions for MBO (such as colonic
stenting or percutaneous gastrostomy tube). Although
there has been research demonstrating improved out-
comes in patients undergoing procedural management
compared to surgical management [4, 42], there were
notably few patients in our dataset who underwent
these procedures alone, so the impact of this limited
number of patients on our results is likely to be min-
imal. However, in patient cohorts where interventional
and endoscopic management of MBO is more preva-
lent, the effect of these procedures on outcomes war-
rants further detailed evaluation. Lastly, we recognize
MBO patients are a heterogenous cohort with a range
of clinical severity and rate of cancer progression. This
is exemplified in the approximately 20% of patients
with relatively long-term survival (see Figs. 4a/b). As
such, future research should assess whether patients
with longer survival times after a diagnosis of MBO de-
rive greater benefit from surgical management given
the potential for some patients in this analysis to live
longer and the equalization of HFD by 180 days post
index MBO diagnosis [43].
Conclusions
Ultimately, in this population-based analysis, medical
management of MBO was associated with fewer
in-hospital deaths, greater discharges to home, and more
Table 4 Length of stay, complications, readmissions, emergency department visits, and re-obstruction for medical and surgical
malignant bowel obstruction patients
Medical Management Surgical Management Adjusted Odds Ratiosa P-value
N % N % OR 95% CI
Length of stay (median, IQR) 5 (3–8) 13 (9–20) 0.91b 0.87b 0.95b < 0.0001
30-day complications 727 21.3% 508 44.0% 2.37 2.04 2.75 < 0.0001
Readmissionsc
7-day 495 15.2% 111 10.9% 0.64 0.51 0.80 0.0001
30-day 1133 34.5% 244 23.4% 0.56 0.48 0.67 < 0.0001
ED visitsc
7-day 149 4.5% 50 4.8% 1.05 0.74 1.48 0.80
30-day 384 11.7% 120 11.5% 1.00 0.79 1.25 0.98
Re-obstruction within 1 yearc 897 27.3% 110 10.5% 0.33 0.26 0.41 < 0.0001
ED emergency department, CI confidence interval
aOdds ratio (except for length of stay which is the regression coefficient) for surgery with medical management treated as reference and adjusted with inverse
probability of treatment weighted (IPTW) analyses using propensity scores created from: age, race, gender, cancer diagnoses, presence of ascites, Elixhuaser
comorbidity index score, and DNR status
bRegression coefficient for log-transformed LOS adjusted with IPTW; with retransformation, indicates a 2.5-fold increase in LOS for surgical patients
cexcluding patients who died at date of discharge (N = 4327), ED visits not associated with hospital admission
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HFDs at 30- and 90-days with equivalent survival to surgi-
cal management. These data highlight the potential bene-
fits of medical management of MBO in advanced cancer
patients and warrant careful consideration, including
whether surgery is indicated, when determining end-of-life
treatment goals in this vulnerable patient population.
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